These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

538 related articles for article (PubMed ID: 19041685)

  • 41. Involvement of interferon regulatory factor 1 and S100C/A11 in growth inhibition by transforming growth factor beta 1 in human hepatocellular carcinoma cells.
    Miyazaki M; Sakaguchi M; Akiyama I; Sakaguchi Y; Nagamori S; Huh NH
    Cancer Res; 2004 Jun; 64(12):4155-61. PubMed ID: 15205326
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Suppression of TG-interacting factor sensitizes arsenic trioxide-induced apoptosis in human hepatocellular carcinoma cells.
    Liu ZM; Tseng JT; Hong DY; Huang HS
    Biochem J; 2011 Sep; 438(2):349-58. PubMed ID: 21649584
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Mybl2 expression is under genetic control and contributes to determine a hepatocellular carcinoma susceptible phenotype.
    Frau M; Ladu S; Calvisi DF; Simile MM; Bonelli P; Daino L; Tomasi ML; Seddaiu MA; Feo F; Pascale RM
    J Hepatol; 2011 Jul; 55(1):111-9. PubMed ID: 21419759
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Swainsonine inhibits growth and potentiates the cytotoxic effect of paclitaxel in hepatocellular carcinoma in vitro and in vivo.
    You N; Liu W; Wang T; Ji R; Wang X; Gong Z; Dou K; Tao K
    Oncol Rep; 2012 Dec; 28(6):2091-100. PubMed ID: 22993037
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A synthetic uracil derivative with antitumor activity through decreasing cyclin D1 and Cdk1, and increasing p21 and p27 in MCF-7 cells.
    Marchal JA; Núñez MC; Suárez I; Díaz-Gavilán M; Gómez-Vidal JA; Boulaiz H; Rodríguez-Serrano F; Gallo MA; Espinosa A; Aránega A; Campos JM
    Breast Cancer Res Treat; 2007 Nov; 105(3):237-46. PubMed ID: 17124554
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Growth inhibition and gene induction in human hepatocellular carcinoma cell exposed to sodium 4-phenylbutanoate.
    Wang CT; Meng M; Zhang JC; Jin CJ; Jiang JJ; Ren HS; Jiang JM; Qin CY; Yu DQ
    Chin Med J (Engl); 2008 Sep; 121(17):1707-11. PubMed ID: 19024104
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Involvement of down-regulation of Cdk2 activity in hepatocyte growth factor-induced cell cycle arrest at G1 in the human hepatocellular carcinoma cell line HepG2.
    Tsukada Y; Tanaka T; Miyazawa K; Kitamura N
    J Biochem; 2004 Nov; 136(5):701-9. PubMed ID: 15632311
    [TBL] [Abstract][Full Text] [Related]  

  • 48. 7,8-dihydroxyflavone induces G1 arrest of the cell cycle in U937 human monocytic leukemia cells via induction of the Cdk inhibitor p27 and downregulation of pRB phosphorylation.
    Park HY; Kim GY; Hyun JW; Kim ND; Kim CG; Kim WJ; Yoo YH; Choi YH
    Oncol Rep; 2012 Jul; 28(1):353-7. PubMed ID: 22552501
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Water extract of Hedyotis Diffusa Willd suppresses proliferation of human HepG2 cells and potentiates the anticancer efficacy of low-dose 5-fluorouracil by inhibiting the CDK2-E2F1 pathway.
    Chen XZ; Cao ZY; Chen TS; Zhang YQ; Liu ZZ; Su YT; Liao LM; Du J
    Oncol Rep; 2012 Aug; 28(2):742-8. PubMed ID: 22641337
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Induction of cell cycle arrest via the p21, p27-cyclin E,A/Cdk2 pathway in SMMC-7721 hepatoma cells by clioquinol.
    Huang Z; Wang L; Chen L; Zhang Y; Shi P
    Acta Pharm; 2015 Dec; 65(4):463-71. PubMed ID: 26677902
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Inhibitory effect of wild-type RASSF1A gene expression on proliferation of hepatocellular carcinoma QGY-7703 cells].
    Rui L; Xue WJ; Li P; Wang ZW; Wang P; Li HX
    Ai Zheng; 2008 Sep; 27(9):924-8. PubMed ID: 18799029
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Roles of estrogen receptor and p21(Waf1) in bortezomib-induced growth inhibition in human breast cancer cells.
    Maynadier M; Shi J; Vaillant O; Gary-Bobo M; Basile I; Gleizes M; Cathiard AM; Wah JL; Sheikh MS; Garcia M
    Mol Cancer Res; 2012 Nov; 10(11):1473-81. PubMed ID: 22964432
    [TBL] [Abstract][Full Text] [Related]  

  • 53. SLXM-2, a derivative of cyclophosphamide: mechanism of growth inhibition on hepatocarcinoma 22 cells.
    Pang LP; Huang W; Sun Q; Guo W; Li RT; Cui JR
    Anticancer Drugs; 2008 Feb; 19(2):167-74. PubMed ID: 18176113
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Up-regulation of p21CIP1 expression mediated by ERK-dependent and -independent pathways contributes to hepatocyte growth factor-induced inhibition of HepG2 hepatoma cell proliferation.
    Shirako E; Hirayama N; Tsukada Y; Tanaka T; Kitamura N
    J Cell Biochem; 2008 May; 104(1):176-88. PubMed ID: 18004740
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype.
    Colado E; Alvarez-Fernández S; Maiso P; Martín-Sánchez J; Vidriales MB; Garayoa M; Ocio EM; Montero JC; Pandiella A; San Miguel JF
    Haematologica; 2008 Jan; 93(1):57-66. PubMed ID: 18166786
    [TBL] [Abstract][Full Text] [Related]  

  • 56. KLF6 transcription factor protects hepatocellular carcinoma-derived cells from apoptosis.
    Sirach E; Bureau C; Péron JM; Pradayrol L; Vinel JP; Buscail L; Cordelier P
    Cell Death Differ; 2007 Jun; 14(6):1202-10. PubMed ID: 17347668
    [TBL] [Abstract][Full Text] [Related]  

  • 57. SarCNU-induced G2/M arrest in hepatoma cells is mediated by a p53-independent phosphorylation of cdc-2 at Tyr15.
    Hung H; Pierce CK; Chee SK; Lawrence P; Hung NT
    J Cell Physiol; 2005 Sep; 204(3):785-91. PubMed ID: 15754328
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Inhibition of cell growth and induction of G1-phase cell cycle arrest in hepatoma cells by steroid extract from Meretrix meretrix.
    Wu TH; Yang RL; Xie LP; Wang HZ; Chen L; Zhang S; Zhao Y; Zhang RQ
    Cancer Lett; 2006 Feb; 232(2):199-205. PubMed ID: 16458116
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma.
    Gordon GJ; Mani M; Maulik G; Mukhopadhyay L; Yeap BY; Kindler HL; Salgia R; Sugarbaker DJ; Bueno R
    Cancer Chemother Pharmacol; 2008 Apr; 61(4):549-58. PubMed ID: 17522864
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Loss of 9p leads to p16INK4A down-regulation and enables RB/E2F1-dependent cell cycle promotion in gastrointestinal stromal tumours (GISTs).
    Haller F; Löbke C; Ruschhaupt M; Cameron S; Schulten HJ; Schwager S; von Heydebreck A; Gunawan B; Langer C; Ramadori G; Sültmann H; Poustka A; Korf U; Füzesi L
    J Pathol; 2008 Jul; 215(3):253-62. PubMed ID: 18438954
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.